Online Articles: Clinical and Laboratory ObservationsHaploidentical Stem Cell Transplant With Post-transplant Cyclophosphamide for Chediak-Higashi Syndrome: A Very Rare Case ReportSachdev, Mansi MD; Bansal, Minakshi MD; Chakraborty, Sohini FNB; Hamal, Sushma MD; Bhargava, Rahul DM; Dua, Vikas FNB Author Information Department of Hematology, Pediatric Hemato-Oncology and Bone Marrow Transplant, Fortis Memorial Research Institute (FMRI), Gurugram, Haryana, India The authors declare no conflict of interest. Reprints: Mansi Sachdev, MD, Department of Hematology, Pediatric Hemato-Oncology and Bone Marrow Transplant, Fortis Memorial Research Institute, Sector-44 (Opposite Huda City Centre Metro Station), Gurugram, Haryana 122002, India (e-mail: [email protected]). Journal of Pediatric Hematology/Oncology: October 2021 - Volume 43 - Issue 7 - p e1030-e1032 doi: 10.1097/MPH.0000000000001977 Buy Metrics Abstract Chediak-Higashi syndrome is a rare immunodeficiency disorder for which hematopoietic stem cell transplant (HSCT) is the only curative treatment option. HSCT only corrects the hematologic and immunologic manifestations of the disease but neurologic complications may still progress after transplant. Haploidentical HSCT (haplo-HSCT) has evolved as a feasible alternative for patients with primary immunodeficiency. More recently, there has been use of haplo-HSCT with post-transplant cyclophosphamide. However, only 4 cases of Chediak-Higashi syndrome have been reported using this approach. Here, the authors describe a case of a 17-month-old boy who was successfully treated by haplo-HSCT with reduced-toxicity conditioning (fludarabine/treosulfan/melphalan) and post-transplant cyclophosphamide. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.